Literature DB >> 21079905

[Treatment of not-with cystic fibrosis associated forms bronchiectasis (non-CF bronchiectasis)].

J Rademacher1, M W Pletz, T Welte.   

Abstract

Bronchiectasis has become more rarely because of the development of antibiotic therapy and vaccination. At present the great majority of bronchiectasis is more likely caused by congenital disorders than by infective reasons. Therapeutic strategies based on the experiences from cystic fibrosis and chronic obstructive pulmonary disease are not always conferrable to patients suffering from bronchiectasis. There are not enough controlled studies to give evidence-based recommendations in the treatment of bronchiectasis, which are not associated with cystic fibrosis. Goals in the treatment are improvement of the mucociliar clearance, the therapy of infections and treatment of inflammation. Currently several agents are under examination. To improve the prognosis and therapy options it would be reasonable to build up a national register for patients with bronchiectasis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21079905     DOI: 10.1007/s00108-010-2716-0

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  34 in total

1.  Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors.

Authors:  J Angrill; C Agustí; R de Celis; A Rañó; J Gonzalez; T Solé; A Xaubet; R Rodriguez-Roisin; A Torres
Journal:  Thorax       Date:  2002-01       Impact factor: 9.139

2.  Inhaled fluticasone in bronchiectasis: a 12 month study.

Authors:  K W Tsang; K C Tan; P L Ho; G C Ooi; J C Ho; J Mak; G L Tipoe; C Ko; C Yan; W K Lam; M Chan-Yeung
Journal:  Thorax       Date:  2005-03       Impact factor: 9.139

Review 3.  Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma.

Authors:  C J Cates; J A Crilly; B H Rowe
Journal:  Cochrane Database Syst Rev       Date:  2006-04-19

4.  Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group.

Authors:  A E O'Donnell; A F Barker; J S Ilowite; R B Fick
Journal:  Chest       Date:  1998-05       Impact factor: 9.410

5.  Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis.

Authors:  E Daviskas; S D Anderson; S Eberl; H K Chan; G Bautovich
Journal:  Am J Respir Crit Care Med       Date:  1999-06       Impact factor: 21.405

6.  Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease.

Authors:  J J Soler-Cataluña; M A Martínez-García; P Román Sánchez; E Salcedo; M Navarro; R Ochando
Journal:  Thorax       Date:  2005-07-29       Impact factor: 9.139

7.  Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: effect on lung function, health status and sputum.

Authors:  Evangelia Daviskas; Sandra D Anderson; Kerry Gomes; Peter Briffa; Belinda Cochrane; H-Kim Chan; Iven H Young; Bruce K Rubin
Journal:  Respirology       Date:  2005-01       Impact factor: 6.424

Review 8.  Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action.

Authors:  Masaharu Shinkai; Markus O Henke; Bruce K Rubin
Journal:  Pharmacol Ther       Date:  2007-12-15       Impact factor: 12.310

Review 9.  Bronchiectasis: not an orphan disease in the East.

Authors:  K W Tsang; G L Tipoe
Journal:  Int J Tuberc Lung Dis       Date:  2004-06       Impact factor: 2.373

10.  Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial.

Authors:  Sanjay Sethi; Paul W Jones; Marlize Schmitt Theron; Marc Miravitlles; Ethan Rubinstein; Jadwiga A Wedzicha; Robert Wilson
Journal:  Respir Res       Date:  2010-01-28
View more
  2 in total

Review 1.  Bronchiectasis--diagnosis and treatment.

Authors:  Jessica Rademacher; Tobias Welte
Journal:  Dtsch Arztebl Int       Date:  2011-12-02       Impact factor: 5.594

Review 2.  [Pseudomonas aeruginosa infections in chronic obstructive pulmonary disease : Role of long-term antibiotic treatment].

Authors:  G G U Rohde; T Welte
Journal:  Internist (Berl)       Date:  2017-11       Impact factor: 0.743

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.